{"filings":[{"id":95120,"accession_number":"0001740797-26-000011","cik":1740797,"company_name":"AVAI BIO, INC.","ticker":"AVAI","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["1.02","9.01"],"status":"ready","headline":"AVAI Bio and Ainnova Tech mutually terminate JV agreement as of May 7, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["No penalties incurred; all obligations and liabilities under the License Agreement (Nov 8, 2024) released.","Joint venture Ai-Nova Acquisition Corp. (AAC) to be formally dissolved per Nevada law.","Each party retains its own intellectual property; all cross-licenses revoked.","Both parties execute mutual releases of all claims arising from the JV.","Company states the termination reflects independent business strategies going forward."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":26267926.55,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107958,"accession_number":"0001740797-26-000005","cik":1740797,"company_name":"AVAI BIO, INC.","ticker":"AVAI","form_type":"8-K","filed_at":"2026-02-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Avant Technologies renamed Avaí Bio, Inc. effective Feb 3, 2026; AVAI ticker unchanged","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Certificate of Amendment filed with Nevada on Feb 3, 2026, to change corporate name to Avaí Bio, Inc.","Trading symbol will remain AVAI; no change to stock trading or listing.","Company is a Nevada corporation; principal address unchanged at Las Vegas, NV.","Name change is effective as of Feb 3, 2026; no impact on shareholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":26267926.55,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124372,"accession_number":"0001740797-25-000049","cik":1740797,"company_name":"AVAI BIO, INC.","ticker":"AVAI","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Avant Technologies forms joint venture Insulinova with Austrianova for diabetes cell therapy","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["AVAI and Austrianova each hold 50% of Insulinova, a JV for encapsulated insulin cell diabetes treatments.","AVAI contributes up to $1.5M in capital over 18 months for operations, plus an optional $8.5M loan for clinical testing.","Austrianova provides exclusive license to its cell encapsulation technology; Kenn Kerr CEO, Walter Günzburg Chairman.","This agreement supersedes the prior JV from Sept 19, 2025, which included Art-Islets as a party."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":26267926.55,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141047,"accession_number":"0001740797-25-000047","cik":1740797,"company_name":"AVAI BIO, INC.","ticker":"AVAI","form_type":"8-K","filed_at":"2025-09-18T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Avant Technologies enters joint venture with Austrianova to form Klothonova for Klotho-based therapies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["AVAI and Austrianova form Klothonova Inc., a 50/50 joint venture to develop treatments for Alzheimer's, heart disease, cancer, kidney disease, and longevity.","AVAI will fund Klothonova's operations for 18 months up to $1.5M in exchange for 1.5M shares (50% ownership).","Austrianova contributes its proprietary cell encapsulation technology and IP as an exclusive license to Klothonova.","Potential additional $8.5M loan from AVAI for clinical development; if AVAI declines, Austrianova can pursue development outside Klothonova.","Kenn Kerr named CEO; Walter H. Günzburg, Ph.D., appointed Chairman of the Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":26267926.55,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141046,"accession_number":"0001740797-25-000045","cik":1740797,"company_name":"AVAI BIO, INC.","ticker":"AVAI","form_type":"8-K","filed_at":"2025-09-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Avant Technologies files to change name to Avaí Bio, Inc.","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed FINRA application on Sept 15, 2025 to rename as Avaí Bio, Inc.","Ticker symbol 'AVAI' unchanged until FINRA declares corporate action effective.","Name change intended to better reflect current business of the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":26267926.55,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158830,"accession_number":"0001740797-25-000030","cik":1740797,"company_name":"AVAI BIO, INC.","ticker":"AVAI","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["1.02","9.01"],"status":"ready","headline":"Avant Technologies terminates ELOC with GHS Investments, plans new equity line with $2 floor price","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Effective May 13, 2025, the company and GHS Investments mutually terminated the July 17, 2024 Equity Financing Agreement (ELOC).","Termination was based on evaluation that existing terms, including the minimum floor price, no longer aligned with business strategy.","Company will withdraw its pending Form S-1 and pursue a new ELOC with a higher minimum floor price of $2.00 per share.","Both parties confirmed no further obligations or liabilities under the terminated agreements.","New ELOC structure is intended to improve terms, compliance, and shareholder alignment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":26267926.55,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177234,"accession_number":"0001740797-25-000020","cik":1740797,"company_name":"AVAI BIO, INC.","ticker":"AVAI","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Avant Technologies expands joint venture territory to global license; extends conditions deadline to Nov 2025","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Addendum expands Ainnova’s Technology Portfolio license to global territory (previously North America and Europe).","Conditions satisfaction deadline under Joint Venture Agreement extended from May 8, 2025 to November 8, 2025.","Parties agree to possible merger terms as per Term Sheet signed September 21, 2024.","Ai-nova Acquisition Corp, LLC formed December 6, 2024; jointly represented by CEOs of Avant and Ainnova."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":26267926.55,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193996,"accession_number":"0001740797-24-000056","cik":1740797,"company_name":"AVAI BIO, INC.","ticker":"AVAI","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Avant to fund up to $20M, forms 50/50 JV with Ainnova for retina AI tech","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Avant contributes up to $20M in capital over 12 months to new JV 'Ai-Nova Acquisition Corp'.","Ainnova contributes Vision AI technology portfolio for retinal disease detection and scanning.","Ownership split 50% Avant, 50% Ainnova; JV to issue 2,000,000 shares.","Profit distribution: first to Ainnova for contributed business value, then Avant for capital, then pro-rata.","Territories include US, Canada, Europe; JV to seek third-party licensing and strategic transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":26267926.55,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193995,"accession_number":"0001740797-24-000049","cik":1740797,"company_name":"AVAI BIO, INC.","ticker":"AVAI","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Avant Technologies appoints Chris Winter as COO; receives quarterly RSA of 100,000 shares","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chris Winter appointed COO effective Nov 1, 2024; reports directly to the Board.","Compensation: quarterly RSA of 100,000 shares (67,000 prorated first quarter) at 85% of 30-day VWAP, floor $0.10.","Company pays tax gross-up bonus within 10 days of each share issuance.","Shares fully vested upon issuance; accelerated vesting on change of control (≥50% sale).","No relocation required; employee uses own laptop and phone."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":26267926.55,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210339,"accession_number":"0001740797-24-000047","cik":1740797,"company_name":"AVAI BIO, INC.","ticker":"AVAI","form_type":"8-K","filed_at":"2024-09-10T23:59:59+00:00","items":["1.02","5.02","9.01"],"status":"ready","headline":"Avant Tech terminates $2.2M Wired4Health asset purchase; CFO replaced","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["APA with Wired4Health for $2.2M consideration cancelled; remaining promissory note balance void.","Payments already made retained by Wired4Health; both parties mutually released from all claims.","CFO William Hisey resigned Sept 9, 2024; COO Vitalis Racius appointed CFO, retains other roles.","No conflicts reported with Hisey's departure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":26267926.55,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210338,"accession_number":"0001740797-24-000035","cik":1740797,"company_name":"AVAI BIO, INC.","ticker":"AVAI","form_type":"8-K","filed_at":"2024-07-22T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Avant Technologies enters $20M equity financing agreement with GHS Investments at 80% discount","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $20M of common stock over 24 months; purchase price is 80% of lowest traded price in prior 10 trading days.","After NASDAQ uplist, price becomes 90% of lowest VWAP with $0.50 floor; puts capped at $500K each.","Company can initiate puts only when registration effective; GHS ownership limited to 4.99% of outstanding shares.","First closing requires $8,000 deposit to investor's legal counsel for transaction costs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":26267926.55,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210337,"accession_number":"0001740797-24-000033","cik":1740797,"company_name":"AVAI BIO, INC.","ticker":"AVAI","form_type":"8-K","filed_at":"2024-07-15T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Avant Technologies appoints Kenneth L. Waggoner as CEO with $720K salary in shares","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kenneth L. Waggoner named CEO effective July 10, 2024; 1-year term renewable automatically.","Base salary $720k annual paid in common shares quarterly at 20-day VWAP; increases to $1.44M upon national exchange listing.","Additional bonus of 10% of net equity financing raised if deemed sufficient by Board.","Former interim CEO Hisey reappointed as CFO; Racius reappointed as COO while remaining Director and Treasurer.","CEO has 45 years experience including senior roles at Chevron and PharmaCyte Biotech."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":26267926.55,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228650,"accession_number":"0001393905-24-000214","cik":1740797,"company_name":"AVAI BIO, INC.","ticker":"AVAI","form_type":"8-K","filed_at":"2024-06-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Avant Technologies signs binding LOI to acquire up to 50 supercomputer servers for $50M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Binding LOI with Flow Wave, LLC to acquire up to 50 immersible supercomputer servers for $50M cash.","Payment via $50M promissory note, 5% interest, six monthly payments after Avant raises at least $20M.","If Avant fails to pay within 6 months post capital raise, deal voids and servers return to Flow Wave.","Transaction subject to definitive agreement, board/regulatory approvals, due diligence, and Avant shareholder vote.","Avant CEO states acquisition positions company in supercomputer-driven data center industry."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":26267926.55,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228649,"accession_number":"0001740797-24-000019","cik":1740797,"company_name":"AVAI BIO, INC.","ticker":"AVAI","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Avant Technologies designates Series B Convertible Preferred Stock for Wired4Health asset acquisition","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed Certificate of Designation for 1M shares of Series B Convertible Preferred Stock.","Series B issued as partial consideration for acquiring Wired4Health assets; total consideration $2.2M.","Conversion price set at lesser of $1.00 per share or 30-day VWAP of common stock on OTC Markets.","Conversion subject to 4.99% beneficial ownership limitation and daily sales cap of 25% of total volume.","Preferred Stock has aggregate stated value of $1M; Secured Note of $1.2M also issued."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":26267926.55,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228648,"accession_number":"0001740797-24-000015","cik":1740797,"company_name":"AVAI BIO, INC.","ticker":"AVAI","form_type":"8-K","filed_at":"2024-04-26T23:59:59+00:00","items":["1.01","3.02","5.02","9.01"],"status":"ready","headline":"Avant Technologies CEO & COO resign; William Hisey named Interim CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Timothy Lantz resigned as CEO and Director effective April 24, 2024, without conflicts with the Board.","Angela Harris resigned as COO and Jared Pelski as VP Business Development, effective April 24, 2024.","William Hisey appointed Interim CEO effective April 25, 2024; base salary $4,000/month plus quarterly RSA of 70,000 shares.","All three prior employment agreements (Lantz, Pelski, Harris) canceled by mutual consent; no claims outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":26267926.55,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228647,"accession_number":"0001740797-24-000013","cik":1740797,"company_name":"AVAI BIO, INC.","ticker":"AVAI","form_type":"8-K","filed_at":"2024-04-08T23:59:59+00:00","items":["1.01","2.01","2.03","3.02","9.01"],"status":"ready","headline":"Avant Technologies acquires Wired4Health assets for $2.2M in secured note and preferred stock","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired full-stack software development and cloud services assets from Wired4Health for $2.2M total consideration.","Paid $1.2M via secured promissory note (24 monthly installments of $52,427, 5% interest) and $1M in Series B Convertible Preferred Stock.","Preferred Stock convertible at lesser of $1.00/share or 30-day VWAP, with 4.99% beneficial ownership cap and 25% daily volume leak-out.","Assets include agreements with Sentry Data Systems/Craneware and Respec, Inc., website, employee contracts, and goodwill.","Secured note is collateralized by acquired assets; Seller may file UCC-1 financing statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":26267926.55,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247293,"accession_number":"0001740797-24-000007","cik":1740797,"company_name":"AVAI BIO, INC.","ticker":"AVAI","form_type":"8-K","filed_at":"2024-01-31T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Avant Technologies appoints Angela Harris as COO effective Feb 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Annual base salary of $275,000 plus cash bonus up to 35% of base, accrued until company raises funds.","Initial ISO grant of 2% of outstanding common stock at $0.01 strike, 4-year vesting with 1-year cliff.","One-time RSA bonus of $500,000 if listed on Nasdaq or other national exchange, payable in shares at 15% discount to VWAP.","Cash compensation and bonuses accrued and paid within 5 business days after sufficient funds are raised.","Mrs. Harris will report to the President/CEO/CFO and be part of Senior Management Team."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":26267926.55,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247292,"accession_number":"0001740797-24-000003","cik":1740797,"company_name":"AVAI BIO, INC.","ticker":"AVAI","form_type":"8-K","filed_at":"2024-01-19T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Avant Technologies hires Jared Pelski as VP of Business Development with $200K salary and equity incentives","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jared Pelski appointed Vice President – Business Development effective January 17, 2024.","Base salary of $200,000 per year, annual cash bonus up to 25% of base, and one-time $25,000 sign-on bonus.","Initial ISO grant for 0.6% of outstanding common stock at $0.01 strike price, 4-year vesting with 1-year cliff.","Eligible for Restricted Stock Awards at 15% discount to VWAP; up-listing bonus of $300,000 RSA if Nasdaq-listed.","Commission on sales and origination bonus for capital raised using Lehman scale."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":26267926.55,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264727,"accession_number":"0001740797-23-000083","cik":1740797,"company_name":"AVAI BIO, INC.","ticker":"AVAI","form_type":"8-K","filed_at":"2023-12-12T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Avant Technologies signs co-development deal with Wired-4-Tech for AI submersion cooling infrastructure","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Wired-4-Tech will exclusively develop proprietary hardware/software for Avant's AI infrastructure and submersion cooling systems.","Avant receives exclusive perpetual license and full IP assignment upon completion and payment.","Payment terms require Avant to raise working capital; initial deposit mutually agreed to start work.","Agreement term is three years; termination allowed for material breach with 30-day cure for Avant, 45-day for Developer.","IP reverts to Wired-4-Tech if Avant becomes insolvent; Avant's licensees become direct licensees of Developer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":26267926.55,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264726,"accession_number":"0001740797-23-000075","cik":1740797,"company_name":"AVAI BIO, INC.","ticker":"AVAI","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["1.01","3.02","5.02","9.01"],"status":"ready","headline":"Avant Technologies appoints Timothy Lantz as CEO; prior CEO Racuis remains CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Timothy Lantz named Director and CEO effective Nov 3, 2023; replaces Vitalis Racuis who vacates CEO but stays CFO/Treasurer.","Lantz receives $480k annual base salary, 50% annual cash bonus, and quarterly RSA of $375k (15% VWAP discount) plus 3% ISO grant.","Paul Averill resigned as COO effective Nov 3; no disagreement cited; potential consulting agreement under Lantz.","Equity grants to Lantz issued as unregistered securities under Section 4(a)(2); no general solicitation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":26267926.55,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264725,"accession_number":"0001740797-23-000072","cik":1740797,"company_name":"AVAI BIO, INC.","ticker":"AVAI","form_type":"8-K","filed_at":"2023-10-06T23:59:59+00:00","items":["2.03","3.02","9.01"],"status":"ready","headline":"Avant Technologies issues $126K convertible note to 1800 Diagonal Lending LLC","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $126,000 convertible note (original issue discount of $21,000) for net proceeds of $105,000.","Note matures March 2, 2025, bears 8% interest, convertible after 180 days at 85% of lowest trading price.","Conversion capped at 4.99% beneficial ownership; company repaid prior $125,100 note on Sept 26, 2023 for $136,393.","Proceeds used for general working capital; securities issued under Section 4(a)(2) exemption."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":26267926.55,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281954,"accession_number":"0001740797-23-000069","cik":1740797,"company_name":"AVAI BIO, INC.","ticker":"AVAI","form_type":"8-K","filed_at":"2023-08-18T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Avant signs $375K/quarter advisor deal with Timothy Lantz for product & market strategy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Timothy Lantz appointed Chief Product & Market Strategy Advisor effective Aug 1, 2023; receives $375K quarterly (40% cash min, rest in stock at 15% VWAP discount, floor $0.10).","If Avant lists on Nasdaq, quarterly fee increases to $450K retroactive to Aug 1, 2023; payments then in cash.","Term runs Aug 1, 2023 to July 31, 2024, extendable by mutual consent; 30-day termination for convenience by either party.","Advisor currently serves as senior executive at a private AI/tech company; agreement acknowledges outside work.","Shares issued are unregistered; advisor accredited investor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":26267926.55,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281953,"accession_number":"0001740797-23-000057","cik":1740797,"company_name":"AVAI BIO, INC.","ticker":"AVAI","form_type":"8-K","filed_at":"2023-07-26T23:59:59+00:00","items":["1.01","3.02","5.02","9.01"],"status":"ready","headline":"Avant Technologies appoints Danny Rittman as CISO with $300K salary payable in shares","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Danny Rittman appointed Chief Information Security Officer (CISO) effective July 24, 2023.","Base salary $300K/year payable in shares quarterly based on 20-day VWAP; rises to $600K upon up-listing to a national exchange.","One-time $50K cash payment due within 30 days after company raises sufficient equity or working capital.","Rittman concurrently serves as CTO of GBT Technologies (GTCH); company acknowledges no conflict with existing agreements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":26267926.55,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281952,"accession_number":"0001740797-23-000060","cik":1740797,"company_name":"AVAI BIO, INC.","ticker":"AVAI","form_type":"8-K/A","filed_at":"2023-07-26T23:59:59+00:00","items":["5.02","1.01","3.02","9.01"],"status":"ready","headline":"Avant Technologies names Danny Rittman CISO; $300K annual salary paid in shares, contingent cash bonus","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointment effective July 24, 2023; base salary $300,000/year in common shares, rising to $600,000 on up-listing to national exchange.","Quarterly stock issuances equal $75,000 divided by 20-day VWAP; one-time $50,000 cash bonus due within 30 days of equity financing.","Term expires August 1, 2024; either party may terminate without cause on 30 days' notice.","Rittman concurrently serves as CTO of GBT Technologies (OTC: GTCH); company states no conflict with his new role."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":26267926.55,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281955,"accession_number":"0001740797-23-000055","cik":1740797,"company_name":"AVAI BIO, INC.","ticker":"AVAI","form_type":"8-K","filed_at":"2023-07-19T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"Avant Technologies (f/k/a Trend Innovations) changes name and ticker to AVAI, effective July 19, 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company changed name from Trend Innovations Holding Inc. to Avant Technologies Inc. via Certificate of Amendment filed May 24, 2023.","Ticker symbol changed from 'TREN' to 'AVAI' on OTC Markets, effective July 19, 2023, after FINRA announcement on July 18.","Name Change and Symbol Change do not affect rights of security holders; existing stock certificates remain valid.","Certificates reflecting new name will be issued when old certificates are tendered for exchange or transfer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":26267926.55,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300972,"accession_number":"0001740797-23-000039","cik":1740797,"company_name":"AVAI BIO, INC.","ticker":"AVAI","form_type":"8-K","filed_at":"2023-05-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Trend Innovations files FINRA application to change name to Avant Technologies Inc.","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed FINRA application on May 23, 2023 to change name from Trend Innovations Holding Inc. to Avant Technologies Inc.","Name change intended to better reflect the company's current business operations.","Trading symbol change also sought but not specified in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":26267926.55,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300971,"accession_number":"0001740797-23-000037","cik":1740797,"company_name":"AVAI BIO, INC.","ticker":"AVAI","form_type":"8-K","filed_at":"2023-05-12T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Trend Innovations engages Percy Kwong as Technology Advisor with quarterly stock compensation up to $250K","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Advisor receives $150K/quarter in common stock (85% of 10-day VWAP, floor $0.10/share) for tech advisory services.","If stock lists on Nasdaq, quarterly fee rises to $250K retroactive to April 15, 2023; term ends May 5, 2024 with possible renewal.","Shares are unregistered; advisor is an accredited investor and bears own taxes; indemnification and insurance required from company.","Advisor retains ownership of independent inventions and may continue work for other companies; agreement terminates for convenience."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":26267926.55,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300970,"accession_number":"0001740797-23-000035","cik":1740797,"company_name":"AVAI BIO, INC.","ticker":"AVAI","form_type":"8-K","filed_at":"2023-05-01T23:59:59+00:00","items":["1.01","3.02","5.02","9.01"],"status":"ready","headline":"Trend Innovations hires Paul Averill as COO with $600K stock salary, up to $1.2M on uplist","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Paul Averill appointed COO effective April 27, 2023; base salary $600K/yr in shares, increasing to $1.2M upon Nasdaq uplisting.","Shares paid quarterly at $150K/quarter based on 20-day VWAP; one-time $150K cash payment after equity raise.","Employment term expires May 1, 2024; either party can terminate with 30 days' notice.","Shares issued under Section 4(a)(2) exemption as unregistered securities to accredited investor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":26267926.55,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300969,"accession_number":"0001740797-23-000032","cik":1740797,"company_name":"AVAI BIO, INC.","ticker":"AVAI","form_type":"8-K","filed_at":"2023-04-28T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Appoints Kenneth L. Waggoner as CEO; salary payable in shares, bonus tied to capital raising","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO base salary $720k/year in common stock, increasing to $1.44M upon uplisting to a national exchange.","Quarterly share payments determined by dividing $180k by 20-day VWAP.","Bonus of at least $200k if Waggoner raises sufficient equity or working capital.","Company to maintain D&O insurance comparable to Nasdaq-listed tech firms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":26267926.55,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300968,"accession_number":"0001740797-23-000030","cik":1740797,"company_name":"AVAI BIO, INC.","ticker":"AVAI","form_type":"8-K","filed_at":"2023-04-24T23:59:59+00:00","items":["1.01","3.02","5.02","9.01"],"status":"ready","headline":"Trend Innovations names new CEO Kenneth Waggoner; ex-CEO Tunevic stays as President","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kenneth L. Waggoner named CEO on Apr 20, 2023, replacing Natalija Tunevic who remains President and director.","Annual base salary of $720,000 in common stock, retroactively increased to $1,440,000 upon listing on a national exchange.","Shares paid quarterly: $180,000 per quarter divided by 20-day VWAP; $2,500/mo health plan also paid in shares.","Agreement term one year from April 20, 2023, auto-renewing; includes confidentiality, invention assignment, and indemnification.","Waggoner has 45 years experience, including as CEO of PharmaCyte Biotech (2013-2022) and partner at Brobeck."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":26267926.55,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300967,"accession_number":"0001740797-23-000028","cik":1740797,"company_name":"AVAI BIO, INC.","ticker":"AVAI","form_type":"8-K","filed_at":"2023-04-14T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Trend Innovations files Certificate of Designation for Series A Preferred Stock issued in Treasure APA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 5,000 Series A Preferred shares at $5,000 stated value each to Treasure Drive Ltd. for technology portfolio.","Preferred shares convertible into common at 5% discount to 5-day VWAP, with 4.99% beneficial ownership limit.","If not up-listed to Nasdaq within 9 months, TD can request unwinding of the Treasure APA.","Certificate of Designation filed as Exhibit 3.1; shares have no voting rights and liquidation preference equal to stated value."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":26267926.55,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300966,"accession_number":"0001740797-23-000022","cik":1740797,"company_name":"AVAI BIO, INC.","ticker":"AVAI","form_type":"8-K","filed_at":"2023-04-03T23:59:59+00:00","items":["1.01","3.02","5.01","9.01"],"status":"ready","headline":"Trend Innovations issues 26M shares for Avant-AI AI system and 5,000 convertible preferred for Instant Fame assets","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired Avant-AI text-generation deep learning system from GBT Tokenize; issued 26M common shares with 9-month lock-up.","Acquired Instant Fame technology portfolio from Treasure Drive for 5,000 convertible preferred shares ($5,000 stated value each) convertible at 5% discount to 5-day VWAP.","Engaged Elentina Group for capital markets services at $75,000 quarterly fee paid in common stock priced at 10-day VWAP (floor $0.10).","Both asset acquisitions include unwind right if company fails to up-list to Nasdaq before lock-up expiration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":26267926.55,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320848,"accession_number":"0001740797-23-000019","cik":1740797,"company_name":"AVAI BIO, INC.","ticker":"AVAI","form_type":"8-K","filed_at":"2023-03-28T23:59:59+00:00","items":["2.03","3.02","9.01"],"status":"ready","headline":"Trend Innovations issues $125,100 convertible note to 1800 Diagonal Lending at 8% interest","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Principal $125,100; purchased at $104,250 (16.6% OID); 8% annual interest; matures June 27, 2024.","Conversion after 180 days at 85% of lowest trading price in prior 20 days; 4.99% ownership cap.","Company granted 1800 Diagonal Lending right of first refusal on future equity offerings under $150k for 9 months.","Proceeds used for general working capital; buyer's expenses of $4,250 reimbursed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":26267926.55,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320847,"accession_number":"0001740797-23-000016","cik":1740797,"company_name":"AVAI BIO, INC.","ticker":"AVAI","form_type":"8-K","filed_at":"2023-03-09T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Trend Innovations increases authorized shares to 520M from 255M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Common stock authorized increased to 500M shares; blank-check preferred to 20M shares.","Certificate of Amendment filed with Nevada Secretary of State on March 6, 2023.","Board gains authority to issue preferred stock with terms set at issuance.","No immediate issuance or dilution announced in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":26267926.55,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}